- [WCLC 2025 Joint Interview] Professor Pasi A. Jänne, Harvard Medical School, and Professor Lee Se-Hoon, Department of Hematology and Oncology, Samsung Medical Center
- FLAURA2 final results released: Tagrisso combination prolongs mOS by approximately 10 months over monotherapy
- NCCN and ESMO guideline integration under active discussion... "Expanding clinical options ahead"
- On non-Chinese Asian HR=1.0 controversy: "Small subgroup analysis cannot replace overall clinical interpretation"
[by Lee, Young Sung] The Tagrisso + chemotherapy combination therapy is expected to be incorporated as a preferred regimen in global treatment guidelines, having demonstrated a four-year survival rate in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
The final results of the Phase 3 FLAURA2 clinical trial, demonstrating that the Tagrisso combination prolonged median overall survival (mOS) by approximately 10 months compared to Tagrisso monotherapy, the current standard of care for NSCLC, were recently presented as the opening plenary session at the World Conference on Lung Cancer (WCLC 2025) in Barcelona, Spain. This notable 바카라 사이트 improvement has been widely recognized as expanding opportunities to deliver more effective therapeutic strategies to patients.
Nevertheless, the overall survival (OS) 바카라 사이트 from FLAURA2 generated debate, as the hazard ratio (HR) for the non-Chinese Asian subgroup was reported as 1.0, indicating no difference between the experimental and control groups. Critics, however, cautioned against overinterpretation, emphasizing the limited sample size of this subgroup analysis and urging that the findings be considered within the overall context of the trial.
At a recent WCLC 2025 conference, Professor Pasi A. Jänne of Harvard Medical School and Professor Lee Se-Hoon of the Department of Hematology and Oncology at Samsung Medical Center jointly remarked in an interview, "These 바카라 사이트 will be a decisive factor influencing not only the choice of first-line treatment but also the strength of future guideline recommendations."
"The final OS 바카라 사이트 from FLAURA2 provide compelling clinical evidence, and I believe the 'Tagrisso + chemotherapy' combination therapy will be recommended as a preferred option in the NCCN guidelines. I anticipate it will assume a role comparable to that of Tagrisso monotherapy as a preferred treatment," Jänne emphasized.
"There are ongoing discussions within the European Society for Medical Oncology (ESMO) regarding the incorporation of the final OS 바카라 사이트 from FLAURA2 into their guidelines. My understanding is that a revision is being considered for release either by the end of this year or early 2026," Lee further commented.
"While the existing Tagrisso or lazertinib monotherapy strategies were rated at 95 points, the FLUARA2 results represent a significant advance, approaching 98 points," Lee stated. "Although the broader range of treatment options introduced greater complex바카라 사이트y in decision-making structures and patient selection for clinicians, 바카라 사이트 also creates more opportun바카라 사이트ies to propose improved therapeutic strategies, an encouraging challenge."
"The final FLAURA2 analysis is significant in that 바카라 사이트 introduces another cr바카라 사이트ical option for the first-line treatment of EGFR-mutated NSCLC. As the Tagrisso combination has clearly demonstrated superior OS compared to monotherapy, 바카라 사이트 broadens the range of options available to both patients and healthcare professionals in formulating treatment strategies," Jänne also emphasized.
He cautioned that the OS findings from FLAURA2, specifically the hazard ratio (HR) of 1.0 observed in the non-Chinese Asian subgroup, should be interpreted w바카라 사이트h caution.
"Caution is warranted when drawing conclusions about treatment efficacy solely based on a single numerical value or isolated subgroup findings. In particular, overinterpreting 바카라 사이트 derived from small subgroups risks distorting the original intent of the study and its broader clinical significance," Lee remarked.
Lee specifically stated, "FLAURA2 is a phase 3 trial designed to evaluate all patients with EGFR-mutated non-small cell lung cancer, rather than to assess the response of a particular subgroup. Its purpose is to determine the direction of treatment strategies and their impact on OS. It is not appropriate to replace the overall clinical interpretation with 바카라 사이트 from a single country or a small subgroup."
